Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

Sarah-Jane Anderson (), Miranda Murray, David Cella, Robert Grossberg, Debbie Hagins, William Towner, Marcia Wang, Andrew Clark, Amy Pierce, Cyril Llamoso, Peter Ackerman and Max Lataillade
Additional contact information
Sarah-Jane Anderson: GlaxoSmithKline
Miranda Murray: ViiV Healthcare
David Cella: Northwestern University Feinberg School of Medicine
Robert Grossberg: Montefiore Medical Center
Debbie Hagins: Chatham CARE Center
William Towner: Southern California Kaiser Permanente Medical Group
Marcia Wang: GlaxoSmithKline
Andrew Clark: ViiV Healthcare
Amy Pierce: ViiV Healthcare
Cyril Llamoso: ViiV Healthcare
Peter Ackerman: ViiV Healthcare
Max Lataillade: ViiV Healthcare

The Patient: Patient-Centered Outcomes Research, 2022, vol. 15, issue 1, No 11, 143 pages

Abstract: Abstract Introduction Heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) have limited viable antiretroviral regimens available because of multidrug resistance and safety concerns. The first-in-class HIV-1 attachment inhibitor fostemsavir demonstrated efficacy and safety in HTE participants in the ongoing phase III BRIGHTE trial. Objectives We describe patient-reported outcomes (PROs) through week 48. Methods Eligible participants for whom their current regimen was failing were assigned to the randomized cohort (RC; one to two fully active agents remaining) or the nonrandomized cohort (NRC; no fully active agents remaining). PRO assessments included the EQ-5D-3L, EQ-VAS, and Functional Assessment of HIV Infection (FAHI) instruments. Results Both cohorts achieved increases in EQ-5D-3L US- and UK-referenced utility score from baseline at week 24. Mean visual analog scale (VAS) scores in the RC and NRC increased from baseline by 8.7 (95% CI 6.2–11.2) and 5.6 points (95% CI 1.5–9.7) at week 24 and increased from baseline by 9.8 (95% CI 7.0–12.6) and 4.9 points (95% CI 0.6–9.2) at week 48, respectively. Mean increases in FAHI total score from baseline to weeks 24 and 48 in the RC were 6.9 (95% CI 4.2–9.7) and 5.8 (95% CI 2.7–9.0), respectively, whereas mean increases in physical and emotional well-being subscale scores were 2.7 (95% CI 1.9–3.6) and 2.4 (95% CI 1.3–3.4) and 3.2 (95% CI 2.2–4.2) and 2.6 (95% CI 1.6–3.7), respectively, with little to no change in other subscales. Conclusions Improvements in major domains of the EQ-VAS and FAHI through week 48, combined with efficacy and safety results, support the use of fostemsavir for HTE PLWH. Trial Registration Number and Date NCT02362503; February 13, 2015.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-021-00534-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:15:y:2022:i:1:d:10.1007_s40271-021-00534-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-021-00534-y

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().